Supporting Better Outcomes in Wound Care
Merakris Therapeutics Extracellular Wound Care portfolio is based on our proprietary advancements in amniotic fluid processing. We work with world-class academic institutions for a ready supply of product, produced to stringent quality standards.
And the Merakris difference means the highest quality products, fast shipments, technical support and reimbursement guidance.
Dermacyte® Amniotic Wound Care Matrix (Dermacyte Matrix) is a cross-linked human amniotic membrane allograft consisting of an epithelial basal and compact fibroblast layer associated with the membrane.
Dermacyte Matrix provides a protective covering and a support layer for cell attachment and ingrowth during healing of diabetic ulcers, venous ulcers, pressure ulcers, burn, and other dermal ulcerations that include wounds with exposed vital structures such as tendon, muscle, or bone, with minimal adhesion and scarring.
Dermacyte Matrix is intended for use as a protective covering to provide a barrier to underlying tissue.
Merakris offers a comprehensive Reimbursement Guide for providers using Dermacyte.
To get your copy, complete this form and we'll be in touch shortly.
Reimbursement Guide Request
Dermacyte Matrix is regulated by the U.S. Food and Drug Administration (FDA) as a minimally manipulated human allograft tissue under its Human Cells, Tissues, and Tissue-Based Products (HCT/P) guidelines, subject to Section 361 of the Public Health Service Act and 21 CFR 1270 and 1271.